Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (GB:0HKF)
LSE:0HKF
0HKF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.70 - $141.00
Previous CloseN/A
Volume875.00
Average Volume (3M)1.73K
Market Cap
$5.79B
Enterprise Value$4.19B
Total Cash (Recent Filing)$315.35M
Total Debt (Recent Filing)$192.96M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
May 12, 2025EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding48,765,404
10 Day Avg. Volume1,556
30 Day Avg. Volume1,729
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.45
Price to Cash Flow (P/CF)-56.80
P/FCF Ratio244.70
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.89
Enterprise Value/Ebitda-15.26
Forecast
1Y Price Target
$173.50Price Target Upside45.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
EarningsYear-over-year TRx growth for Auvelity has increased to 83%.
Patent SettlementAXSM announced a patent litigation settlement with Hikma Pharmaceuticals for Sunosi, marking a third successful patent litigation outcome regarding Sunosi.
Bears Say
Market PerformanceA slight slowdown for Auvelity was observed in Week 123.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.42% Insiders
19.18% Mutual Funds
4.27% Other Institutional Investors
62.04% Public Companies and Individual Investors
0HKF FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest share price was $64.70 and its highest was $141.00 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $5.79B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is May 12, 2025 which is in 61 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Feb 18, 2025. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$0.539.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -1.29.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,765,404 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -3.569%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in GB:0HKF
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$173.50 (45.35% Upside)
$173.50 (45.35% Upside)
Blogger Sentiment
Bullish
GB:0HKF Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.68%
12-Months-Change
Fundamentals
Return on Equity
-231.63%
Trailing 12-Months
Asset Growth
-3.36%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
0HKF Company Deck
---
0HKF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Read More>---
0HKF Stock 12 Month Forecast
Average Price Target
$173.50
▲(45.35% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Best Analysts Covering 0HKF
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+50.11%
reiterated a buy rating 7 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +50.11% per trade.
---